Oncology

Sutro Biopharma nets $85.4M to drive antibody-drug conjugates Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which includes a pair of antibody-drug conjugates (ADCs).Of its ADC assets, STRO-001 is in phase 1 for lymphoma and multiple myeloma, and STR-002 is slated to enter the clinic for ovarian and endometrial cancer by early 2019..The financing comes five years after the Bay Area biotech's $26 million series D round and brings its total raised to more than $175 million. A few ADCs are already on the market—including Roche's HER2-targeting breast cancer drug Kadcyla and Spectrum Pharma's ...